Jiangbo Pharmaceuticals (JGBO.OB) Announces Inclusion of Its Osteomyelitis Treatment Tablets in the Chinese National Insurance Directory
Jiangbo Pharmaceuticals, Inc., a researcher, developer, producer and marketer of pharmaceutical products in China, recently announced that the company’s Osteomyelitis treatment tablets have been included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory. Also referred to as Kang Gu Sui Yan Pian, the company’s Osteomyelitis treatment tablets are 100 percent herb-based traditional Chinese medicine used to treat bone and bone marrow inflammations. As the exclusive manufacturer of Osteomyelitis treatment tablets in China, the company's tablets offer a milder treatment option compared to chemical drugs for treating long-term osteomyelitis problems. Along…